ViaDerma Statistics
Total Valuation
ViaDerma has a market cap or net worth of 13.50 million.
| Market Cap | 13.50M |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
ViaDerma has 1.23 billion shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 1.23B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +11.01% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 302.00 |
| PB Ratio | -12.84 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.29
| Current Ratio | 0.29 |
| Quick Ratio | 0.27 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.51 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -91.23% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 56.46% |
| Revenue Per Employee | 596 |
| Profits Per Employee | -20,245 |
| Employee Count | 75 |
| Asset Turnover | 0.11 |
| Inventory Turnover | 0.60 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +17.63% in the last 52 weeks. The beta is -0.73, so ViaDerma's price volatility has been lower than the market average.
| Beta (5Y) | -0.73 |
| 52-Week Price Change | +17.63% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 38.99 |
| Average Volume (20 Days) | 533,159 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.01 |
Income Statement
In the last 12 months, ViaDerma had revenue of 44,691 and -1.52 million in losses. Loss per share was -0.00.
| Revenue | 44,691 |
| Gross Profit | 37,629 |
| Operating Income | -593,399 |
| Pretax Income | -1.52M |
| Net Income | -1.52M |
| EBITDA | -592,435 |
| EBIT | -593,399 |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 13,082 in cash and 423,663 in debt, giving a net cash position of -410,581 or -0.00 per share.
| Cash & Cash Equivalents | 13,082 |
| Total Debt | 423,663 |
| Net Cash | -410,581 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | -1.05M |
| Book Value Per Share | -0.00 |
| Working Capital | -1.05M |
Cash Flow
| Operating Cash Flow | -167,361 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 84.20% |
| Operating Margin | -1,327.78% |
| Pretax Margin | -3,397.52% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ViaDerma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -273,883.32% |
| Shareholder Yield | -273,883.32% |
| Earnings Yield | -11.25% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on May 6, 2014. It was a reverse split with a ratio of 0.02.
| Last Split Date | May 6, 2014 |
| Split Type | Reverse |
| Split Ratio | 0.02 |
Scores
ViaDerma has an Altman Z-Score of -33.54. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -33.54 |
| Piotroski F-Score | n/a |